 PALO ALTO, Calif., July 22, 2021 PRNewswire -- Eiger BioPharmaceuticals, Inc. Nasdaq: EIGR, a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it will host a conference call on Thursday, August 5, 2021 at 4:30 PM ET to discuss its financial results and provide a business update for the second quarter 2021. 